[Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
Hypolipaemic effectiveness and unfavourable effects of acipimox and fenofibrate were evaluated in patients with essential hyperlipoproteinaemia type II. The studies were carried out in two groups of 30 patients each. The studied patients were treated for three months with diet, and for another three months one group received acipimox (750 mg/day), and the other group was given fenofibrate (300 mg/day). After three months of pharmacological treatment in both groups a statistically significant decrease was seen of the concentrations of total cholesterol (by 13.8% and 19.3% respectively), LDL cholesterol (by 16.3% and 22.1%). TG (by 22.7% and 28.9%). The increase of HDL cholesterol concentration (twofold increase after fenofibrate) was non-significant. Desired LDL cholesterol values were achieved in eight patients (26.7%) treated with fenofibrate and in two patients (6.6%) receiving acipimox. Both drugs were well tolerated. Unfavourable effects were slight and did not require drug withdrawal.
Chojnowska-Jezierska
J
J
III Klinika Chorób Wewnetrznych WAM.
Jabłoński
S
S
Tkaczewski
W
W
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D011719:Pyrazines; D002784:Cholesterol; C027696:acipimox; D011345:Fenofibrate
Skuteczność kliniczna acipimoxu i fenofibratu u osób z hiperlipoproteinemia typu II.